Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Google Secures Pentagon AI Deal for Classified Projects 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
MAYNARD, Mass., May 08, 2018 -- AquaBounty Technologies, Inc. (NASDAQ:AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation (NYSE:XON), announces the Company’s financial results for the quarter ended March 31, 2018.
Financial and Operational Summary:
- Completed public offering of common shares and warrants, raising net funds of $10.6 million;
- received approval from the U.S. Food and Drug Administration (“FDA”) to raise AquAdvantage® Salmon at the Indiana facility;
- net loss for the three-month period ended March 31, 2018, increased to $2.4 million from $2.1 million in the corresponding period of the previous year, reflecting pre-production costs at the Indiana farm site and commencement of R&D activities at the Rollo Bay hatchery; and
- cash and cash equivalents were $6.9 million (December 31, 2017: $0.5 million).
AquaBounty previously announced that it had received FDA approval to raise AquAdvantage Salmon at its land-based contained facility near Albany, Indiana. However, the Company is currently prevented from importing its AquAdvantage Salmon eggs for the facility from Canada due to the existence of an “Import Alert” pending the FDA’s issuance of final labelling guidance for the product. The Company is fully prepared to comply with labelling requirements and hopes that this process will conclude in the near term.
Ronald Stotish, Chief Executive Officer of AquaBounty, stated: “In this quarter, we achieved our two main objectives of completing our public offering and receiving FDA approval for our Indiana farm site facility. We anticipate stocking the tanks in the coming months.”
About AquAdvantage Salmon – AquAdvantage Salmon is an Atlantic salmon that has been bioengineered to grow to market size in about half the time of a traditional farmed Atlantic salmon. It improves the economics of producing salmon in land-based contained facilities. AquAdvantage Salmon is a healthy, environmentally sustainable alternative to imported farmed Atlantic salmon.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements regarding the potential for and possible timing of the FDA’s issuance of final labeling guidance, the lifting of the Import Alert, the stocking of the Indiana farm site facility with eggs, and the raising of AquAdvantage® Salmon at that facility. Forward-looking statements may be identified with words such as “will,” “may,” “expect,” “plan,” “anticipate,” “upcoming,” “believe,” “estimate,” or similar terminology, and the negative of these terms. Forward-looking statements are not promises or guarantees of future performance and are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Forward-looking statements speak only as of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements. For additional information regarding these and other risks faced by us, please refer to our public filings with the Securities and Exchange Commission (“SEC”), available on the Investors section of our website at www.aquabounty.com and on the SEC’s website at www.sec.gov.
AquaBounty Technologies, Inc.
Consolidated Balance Sheets
(Unaudited)
| As of | ||||||
| March 31, | December 31, | |||||
| 2018 | 2017 | |||||
| Assets | ||||||
| Current assets: | ||||||
| Cash and cash equivalents | $ | 6,839,389 | $ | 492,861 | ||
| Certificate of deposit | 13,045 | 13,422 | ||||
| Other receivables | 217,536 | 183,926 | ||||
| Inventory | 125,293 | 172,363 | ||||
| Prepaid expenses and other current assets | 156,973 | 527,322 | ||||
| Total current assets | 7,352,236 | 1,389,894 | ||||
| Property, plant and equipment, net | 23,599,868 | 21,802,976 | ||||
| Definite-lived intangible assets, net | 181,569 | 184,995 | ||||
| Indefinite-lived intangible assets | 191,800 | 191,800 | ||||
| Other assets | 162,093 | 162,093 | ||||
| Total assets | $ | 31,487,566 | $ | 23,731,758 | ||
| Liabilities and stockholders’ equity | ||||||
| Current liabilities: | ||||||
| Accounts payable and accrued liabilities | $ | 2,092,927 | $ | 2,666,855 | ||
| Current debt | 59,260 | 49,794 | ||||
| Total current liabilities | 2,152,187 | 2,716,649 | ||||
| Long-term debt | 3,001,813 | 3,034,420 | ||||
| Total liabilities | 5,154,000 | 5,751,069 | ||||
| Commitments and contingencies | ||||||
| Stockholders’ equity: | ||||||
| Common stock, $0.001 par value, 200,000,000 shares authorized; | ||||||
| 12,675,533 (2017: 8,895,094) shares outstanding | 12,676 | 8,895 | ||||
| Additional paid-in capital | 137,629,187 | 126,718,186 | ||||
| Accumulated other comprehensive loss | (326,002 | ) | (213,884 | ) | ||
| Accumulated deficit | (110,982,295 | ) | (108,532,508 | ) | ||
| Total stockholders’ equity | 26,333,566 | 17,980,689 | ||||
| Total liabilities and stockholders’ equity | $ | 31,487,566 | $ | 23,731,758 | ||
AquaBounty Technologies, Inc.
Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)
| Three Months Ended | ||||||
| March 31, | ||||||
| 2018 | 2017 | |||||
| Revenues | ||||||
| Product revenues | $ | 19,097 | $ | - | ||
| Costs and expenses | ||||||
| Product costs | 16,232 | - | ||||
| Sales and marketing | 81,647 | 208,288 | ||||
| Research and development | 977,817 | 720,022 | ||||
| General and administrative | 1,386,873 | 1,120,788 | ||||
| Total costs and expenses | 2,462,569 | 2,049,098 | ||||
| Operating loss | (2,443,472 | ) | (2,049,098 | ) | ||
| Other income (expense) | ||||||
| Gain on disposal of equipment | 1,160 | - | ||||
| Interest expense | (5,402 | ) | (5,280 | ) | ||
| Other income (expense), net | (2,073 | ) | (1,365 | ) | ||
| Total other income (expense) | (6,315 | ) | (6,645 | ) | ||
| Net loss | $ | (2,449,787 | ) | $ | (2,055,743 | ) |
| Other comprehensive loss: | ||||||
| Foreign currency translation loss | (112,118 | ) | (14,286 | ) | ||
| Total other comprehensive loss | (112,118 | ) | (14,286 | ) | ||
| Comprehensive loss | $ | (2,561,905 | ) | $ | (2,070,029 | ) |
| Basic and diluted net loss per share | $ | (0.21 | ) | $ | (0.24 | ) |
| Weighted average number of common shares - | ||||||
| basic and diluted | 11,940,874 | 8,400,795 | ||||
For further information, please contact: Dave Conley, Director of Communications AquaBounty Technologies, Inc. 613 294 3078
